PHAXIAM Therapeutics Valuation
Is 2e+40 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 2e+40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 2E40's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 2E40's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2e+40?
Other financial metrics that can be useful for relative valuation.
What is 2e+40's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | €18.47m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 16x |
Enterprise Value/EBITDA | -1.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 2e+40's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.4x | ||
MDG1 Medigene | 5.3x | 18.6% | €31.8m |
CNW co.don | 0.7x | n/a | €6.5m |
PA8 Paion | 0.2x | 30.2% | €2.6m |
HPHA Heidelberg Pharma | 15.3x | 28.7% | €138.4m |
2E40 PHAXIAM Therapeutics | 13.9x | -23.3% | €18.5m |
Price-To-Sales vs Peers: 2E40 is expensive based on its Price-To-Sales Ratio (13.9x) compared to the peer average (6.9x).
Price to Earnings Ratio vs Industry
How does 2e+40's PE Ratio compare vs other companies in the DE Biotechs Industry?
Price-To-Sales vs Industry: 2E40 is expensive based on its Price-To-Sales Ratio (13.9x) compared to the European Biotechs industry average (9.7x).
Price to Sales Ratio vs Fair Ratio
What is 2e+40's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 13.9x |
Fair PS Ratio | 0.7x |
Price-To-Sales vs Fair Ratio: 2E40 is expensive based on its Price-To-Sales Ratio (13.9x) compared to the estimated Fair Price-To-Sales Ratio (0.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | €2.94 | €6.85 +133.0% | 16.8% | €8.00 | €5.70 | n/a | 2 |
May ’25 | €2.86 | €6.85 +139.5% | 16.8% | €8.00 | €5.70 | n/a | 2 |
Apr ’25 | €2.88 | €7.25 +151.7% | 10.3% | €8.00 | €6.50 | n/a | 2 |
Mar ’25 | €2.94 | €9.60 +226.5% | 16.7% | €11.20 | €8.00 | n/a | 2 |
Feb ’25 | €3.61 | €9.60 +165.9% | 16.7% | €11.20 | €8.00 | n/a | 2 |
Jan ’25 | €4.45 | €9.85 +121.3% | 13.7% | €11.20 | €8.50 | n/a | 2 |
Dec ’24 | €4.19 | €9.85 +135.1% | 13.7% | €11.20 | €8.50 | n/a | 2 |
Nov ’24 | €4.52 | €9.85 +117.9% | 13.7% | €11.20 | €8.50 | n/a | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.